Search Within

Ross Levine

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Journal Article (202)
  2. Meeting Abstract (194)
  3. Editorial (11)
  4. Review (9)
  5. Research Letter (5)
  6. Book Section (2)
  7. Guidelines (2)
  8. Book Whole (1)
Groups
  1. Adult Leukemia (426)
  2. Center for Hematologic Malignancies (426)
  3. Center for Molecular Imaging and Biotechnology (426)
  4. Department of Medicine (426)
  5. Executive Committee, Center for Hematologic Malignancies (426)
  6. GSK Faculty (426)

More Groups

People
  1. Martin Tallman (50)
  2. Raajit Rampal (43)
  3. Eytan Stein (40)
  4. Franck Rapaport (28)
  5. Alan Shih (26)
  6. Maria Kleppe (26)

More People

Years
  1. 2024 (9)
  2. 2023 (26)
  3. 2022 (22)
  4. 2021 (25)
  5. 2020 (30)
  6. 2019 (29)

More Years

Publications
  1. Blood (159)
  2. Leukemia (16)
  3. Haematologica (14)
  4. Blood Advances (13)
  5. Cancer Research (12)
  6. Swiss Medical Weekly (11)

More Publications

Publishers
  1. American Society of Hematology (174)
  2. Nature Publishing Group (46)
  3. American Association for Cancer Research (36)
  4. Cell Press (25)
  5. Elsevier Inc. (15)
  6. Ferrata Storti Foundation (14)

More Publishers

Results (426)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pevonedistat with azacitidine in older patients with TP53-mutated AML: A phase 2 study with laboratory correlates
    Research Letter

    Saliba, A. N.; Kaufmann, S. H.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M.; Blum, W.; Schiller, G. J.; Olin, R. L.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study
    Journal Article

    Boucai, L.; Ptashkin, R. N.; Levine, R. L.; Fagin, J. A.
    Clinical Endocrinology (2023)

    Fulltext@MSK | Save
  • DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
    Journal Article

    Vekariya, U.; Toma, M.; Nieborowska-Skorska, M.; Le, B. V.; Caron, M. C.; Kukuyan, A. M.; Sullivan-Reed, K.; Podszywalow-Bartnicka, P.; Chitrala, K. N.; Atkins, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Crizotinib has preclinical efficacy in Philadelphia-negative myeloproliferative neoplasms
    Journal Article

    Gurska, L. M.; Okabe, R.; Schurer, A.; Tong, M. M.; Soto, M.; Choi, D.; Ames, K.; Glushakow-Smith, S.; Montoya, A.; Tein, E.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2)
    Journal Article

    Wood, W. A.; Dilip, D.; Derkach, A.; Grover, N. S.; Elemento, O.; Levine, R.; Thanarajasingam, G.; Batsis, J. A.; Bailey, C.; Kannappan, A.; more...
    PLoS Digital Health (2023)

    Fulltext@MSK | Save
  • AXL tyrosine kinase mediates escape from type II JAK2 inhibition in myeloproliferative neoplasms
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Ghosh, N.; Passweg, J. R.; Angelillo-Scherrer, A.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • Whole genome sequencing comparison of acute myeloid leukemia at presentation and remission predicts patient outcome
    Meeting Abstract

    Moffitt, A. B.; Alexander, J.; Stepansky, A.; Famulare, C.; Lopez, C. A.; Hakim, N.; Wu, V.; Wang, Z.; Kolitz, J. E.; Chiorazzi, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)
    Meeting Abstract

    Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Mutational profile of children with myeloproliferative neoplasms
    Meeting Abstract

    Rutherford, K.; Farnoud, N.; Krishnan, A.; Rampal, R. K.; Levine, R. L.; Kucine, N.
    Blood (2022)

    Fulltext@MSK | Save